Yue Hsin Lin
Fondatore presso LIN BIOSCIENCE, INC.
Patrimonio netto: 77 M $ in data 30/04/2024
Posizioni attive di Yue Hsin Lin
Società | Posizione | Inizio | Fine |
---|---|---|---|
LIN BIOSCIENCE, INC. | Fondatore | 12/05/2016 | - |
Presidente | 12/05/2016 | - | |
Contatto Relazioni con gli Investitori | 12/05/2016 | - | |
Amministratore Delegato | 01/06/2016 | 01/04/2022 | |
BELITE BIO, INC | Amministratore Delegato | 27/03/2018 | - |
Presidente | 27/03/2018 | - | |
Fondatore | 27/03/2018 | - | |
Belite Bio LLC
Belite Bio LLC Pharmaceuticals: MajorHealth Technology Part of Lin BioScience, Inc., Belite Bio LLC is a clinical stage biopharmaceutical drug development company based in San Diego, CA. Tinlarebant has been granted fast track designation and rare pediatric disease designation in the US and orphan drug designation in the EU for the treatment of STGD1. Belite Bio is focused on advancing novel therapeutics targeting retinal degenerative eye diseases with significant unmet medical needs, such as atrophic age-related macular degeneration (AMD) and autosomal recessive Stargardt disease, type 1, or STGD1. The company's lead candidate, Tinlarebant, is a novel oral therapy intended to reduce the accumulation of toxins in the eye that cause STGD1 and contribute to geographic atrophy (GA). Belite Bio is currently conducting a two-year phase 2 study and enrolling patients in a two-year phase 3 study (Dragon) of Tinlarebant in adolescent STGD1 subjects and plans to begin enrolling patients in a two-year phase 3 study (Phoenix) of Tinlarebant in GA in mid-2023. The company was founded in 2016 by Cheng Chi Wang. | Presidente | 01/10/2021 | - |
RBP4 Pty Ltd. | Direttore/Membro del Consiglio | 01/08/2018 | - |
Amministratore Delegato | 01/04/2021 | - | |
Belite Bio Holdings Corp. | Amministratore Delegato | 01/12/2017 | - |
Presidente | 01/06/2016 | - | |
Presidente | 01/10/2021 | - | |
Belite Bio (HK) Ltd. | Direttore/Membro del Consiglio | 01/06/2021 | - |
Storia della carriera di Yue Hsin Lin
Precedenti posizioni note di Yue Hsin Lin
Società | Posizione | Inizio | Fine |
---|---|---|---|
CVie Therapeutics Ltd.
CVie Therapeutics Ltd. BiotechnologyHealth Technology Founded in 2013, CVie Therapeutics Ltd. is a subsidiary of Windtree Therapeutics, Inc. The company is based in Taipei, Taiwan. The Taiwanese company develops and researches drugs. | Direttore operativo | 01/01/2014 | 01/01/2016 |
Presidente | 01/01/2014 | 01/01/2016 | |
OBI PHARMA, INC. | Direttore Tecnico/Scientifico/R&S | 01/01/2010 | 01/01/2014 |
ASLAN PHARMACEUTICALS LIMITED | Direttore Tecnico/Scientifico/R&S | 01/01/2014 | - |
Formazione di Yue Hsin Lin
The University of Sydney | Doctorate Degree |
The Trustees of Columbia University in The City of New York | Masters Business Admin |
University of Hong Kong | Masters Business Admin |
University of Pennsylvania | Undergraduate Degree |
London Business School | Masters Business Admin |
Statistiche
Distribuzione geografica
Stati Uniti | 6 |
Taiwan | 4 |
Australia | 3 |
Posizioni
Chief Executive Officer | 4 |
Chairman | 3 |
Masters Business Admin | 3 |
Settori
Health Technology | 7 |
Consumer Services | 6 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 4 |
---|---|
LIN BIOSCIENCE, INC. | Health Technology |
BELITE BIO, INC | Health Technology |
ASLAN PHARMACEUTICALS LIMITED | Health Technology |
OBI PHARMA, INC. | Health Technology |
Aziende private | 5 |
---|---|
Belite Bio LLC
Belite Bio LLC Pharmaceuticals: MajorHealth Technology Part of Lin BioScience, Inc., Belite Bio LLC is a clinical stage biopharmaceutical drug development company based in San Diego, CA. Tinlarebant has been granted fast track designation and rare pediatric disease designation in the US and orphan drug designation in the EU for the treatment of STGD1. Belite Bio is focused on advancing novel therapeutics targeting retinal degenerative eye diseases with significant unmet medical needs, such as atrophic age-related macular degeneration (AMD) and autosomal recessive Stargardt disease, type 1, or STGD1. The company's lead candidate, Tinlarebant, is a novel oral therapy intended to reduce the accumulation of toxins in the eye that cause STGD1 and contribute to geographic atrophy (GA). Belite Bio is currently conducting a two-year phase 2 study and enrolling patients in a two-year phase 3 study (Dragon) of Tinlarebant in adolescent STGD1 subjects and plans to begin enrolling patients in a two-year phase 3 study (Phoenix) of Tinlarebant in GA in mid-2023. The company was founded in 2016 by Cheng Chi Wang. | Health Technology |
RBP4 Pty Ltd. | |
Belite Bio Holdings Corp. | |
CVie Therapeutics Ltd.
CVie Therapeutics Ltd. BiotechnologyHealth Technology Founded in 2013, CVie Therapeutics Ltd. is a subsidiary of Windtree Therapeutics, Inc. The company is based in Taipei, Taiwan. The Taiwanese company develops and researches drugs. | Health Technology |
Belite Bio (HK) Ltd. |
- Borsa valori
- Insiders
- Yue Hsin Lin
- Esperienza